[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Singapore Eye Research Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":275},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,44,73,98,126,152,178,207,227,253],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100636608","effectiveness-of-multidisciplinary-protocolised-interventions-on-ivt-non-adherence-rates-100636608",false,"NCT07567898","Effectiveness of Multidisciplinary Protocolised Interventions on IVT Non-adherence Rates","The Effectiveness of Multidisciplinary Protocolised Interventions to Reduce Non-adherencE Rates (ADHERE) in Patients With Chronic Macula Diseases Receiving Intravitreal Injections: A Randomised Controlled Trial","ADHERE","Inclusion Criteria:\n\n* Patients with chronic macula disease including those diagnosed with nAMD and DME, who require IVT.\n* This would include treatment naive patients (no IVT in either eye the last 6 months) and previously treated patients who have had IVT in either eye in the last 6 months and require further IVT treatment at the baseline study visit in either eye.\n* Able to provide informed consent and must consent to undergoing the MPI intervention.\n* Speak English or Mandarin.\n* Must be a Singapore resident.\n\nExclusion Criteria:\n\n* Patients who are unwilling or unable to perform CAT testing.\n* Unable to provide informed consent.\n* Significant eye pathology such as cornea problems, glaucoma, or other retinal diseases that may substantially affect vision.\n* Do not speak English or Mandarin fluently.\n* Cognitive impairment (as assessed using 6CIT).\n* Obvious observable physical or hearing disabilities that prevents them from completing the CAT questionnaire and undergoing MPI effectively.","ALL",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this research study is to test whether a personalised care approach improves adherence compared to standard care. Many patients with macular diseases like age-related macular degeneration and diabetic macular edema need regular eye injections to protect their vision. However, some do not adhere to their treatment appointments, risking further vision loss.\n\nYou were selected as a possible participant in this research study because you have been diagnosed with neovascular age-related macular degeneration (nAMD) or diabetic macula edema (DME) requiring intravitreal injection treatment (IVT).\n\nThis research study targets to recruit 200 participants from the Singapore National Eye Centre.\n\nThis study comprises two cohort groups: Cohort 1(Suboptimal CAT scores\u002F Randomized Control trial) and Cohort 2 (Optimal CAT scores\u002FObservation).\n\nIf you agree to take part in this study, the research coordinator will obtain your written consent before proceeding with the study procedures. You will be required to complete CAT assessment (via remote or administered in clinic) and assigned to cohort 1 or cohort 2 based on CAT scores result. If you are assigned to cohort 1, you will be randomly allocated to either the personalized multi-disciplinary protocolized intervention (MPI) or standard care group. Randomization means assigning you to one of two groups by chance, like tossing a coin or rolling a dice.\n\n* MPI group: You will complete a specialized computerized adaptive testing (CAT) quality of life questionnaire. Based on the domain specific scores, you will receive a medical consultation and a referral to nurse educators, optometrists, occupational therapists, or social workers.\n* Standard care group: If you are allocated to this group, you will receive standard care, where doctors make treatment decisions without using the CAT results.\n\nIf you are assigned to cohort 2, you will be placed under prospective observation and undergo routine clinical care.",[26,27,28],"Diabetic Macular Edema","Neovascular (Wet) Age-Related Macular Degeneration","Intravitreal Injection",[30,31],"ADHERE, Macular diseases, Intravitreal injections.","neovascular age-related macular","NOT_YET_RECRUITING","2026-04-28",{"date":35,"type":36},"2026-05-05","ACTUAL",{"date":38,"type":20},"2026-04",{"date":40,"type":20},"2028-09",{"name":42,"class":43},"Singapore Eye Research Institute","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100636524","evaluation-of-the-clinical-efficacy-and-mechanisms-of-cord-plasma-eye-drops-in-the-treatment-of-neuropathic-corneal-pain-100636524","NCT07566806","Evaluation of the Clinical Efficacy and Mechanisms of Cord Plasma Eye Drops in the Treatment of Neuropathic Corneal Pain","Inclusion Criteria:\n\n1. Persistent ocular pain or pain-like symptoms, including burning sensation, allodynia, photoallodynia, stinging, hyperalgesia, throbbing, shooting, sharp, cramping, gnawing, or a feeling of electric shock, with a minimum score of 30% for more than 3 questions in the OPAS questionnaire (see below section for OPAS questionnaire), for at least 3 months;\n2. Presence of corneal nerve abnormalities, including microneuromas, beading, nerve tortuosity, decreased in corneal nerve fiber density (CNFD) or corneal nerve fiber length (CNFL), on IVCM images;\n3. Minimal or no ocular surface fluorescein staining, with the National Eye Institute (NEI) and ocular surface Oxford score \\\u003C2;\n4. Patients who will receive cord plasma eye drops treatment\n\nExclusion Criteria:\n\n1. Presence of active ocular surface diseases, such as active infective keratitis, the presence of epithelial defect or any other conditions that may cause nociceptive pain\n2. Active anterior or posterior blepharitis;\n3. Presence of concomitant ocular diseases that may cause ocular pain, such as uveitis or other ocular inflammatory diseases;\n4. Concurrent treatment with immunosuppressants, such as topical cyclosporin or steroid eye drops\n5. Concurrent use of oral Nonsteroidal anti-inflammatory drugs (NSAID) or other medications that may affect the pain scores","21 Years",{"count":52,"type":20},20,[23],"The goal of this clinical trial is to investigate the efficacy and work of action of cord plasma eye drops in the treatment of neuropathic corneal pain (NCP). The main question it aims to answer if the cord plasma eye drops are effective for the treatment of NCP through its neurotrophic and anti-neuroinflammatory effects.",[56,57],"Neuropathic Pain","Corneal Disease",[59,60,61,62,63],"Neuropathic corneal pain","Cord plasma eye drops","Blood-derived eye drops","Corneal nerves","Tear mediators","RECRUITING","2026-04-27",{"date":35,"type":36},{"date":68,"type":36},"2023-09-16",{"date":70,"type":20},"2027-09-15",{"name":42,"class":43},1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":72},"100631790","comparison-of-myopic-small-incision-lenticule-extraction-smile-with-visumax-500-versus-visumax-800-platforms-100631790","NCT07505264","Comparison of Myopic Small Incision Lenticule Extraction (SMILE) With VISUMAX 500 Versus VISUMAX 800 Platforms","Inclusion Criteria:\n\n* Cycloplegic spherical equivalent of \\>-1.00D\n* Refractive cylinder -2.00 D or less; anisometropia \\\u003C1.00D\n* Best spectacle corrected visual acuity (BSCVA) of 6\u002F12 or better in both eyes\n* Spherical or cylindrical error has progressed at -0.50 D or less per year from date of baseline measurement in both eyes\n* Contact lens wearers must have removed contact lenses at least 2 weeks before the baseline measurement\n* No evidence of irregular astigmatism on corneal topography in both eyes\n\nExclusion Criteria:\n\n* Progressive or unstable myopia and\u002For astigmatism\n* Clinical or corneal topographic evidence of keratoconus\n* Residual, recurrent or active ocular disease such as uveitis, severe dry eyes, severe allergic eye disease, glaucoma, visually significant cataract, and retinal disease\n* Previous corneal surgery or trauma within the corneal flap zone\n* Patent corneal vascularization within 1 mm of the corneal flap zone\n* Taking systemic medications likely to affect wound healing, such as corticosteroids and antimetabolites\n* Systemically immunocompromised or systemic disease likely to affect wound healing, such as diabetes, connective tissue disease, and severe atopy; pregnant or nursing",{"count":80,"type":20},100,[23],"Small incision lenticule extraction (SMILE) procedure is a well-known procedure for the correction of myopia. The purpose of this research study is to compare the two SMILE procedures with different laser platforms (VISUMAX 500 and VISUMAX 800) used for the correction of short-sightedness. The VISUMAX 800 and VISUMAX 500 perform the same procedure, but the VISUMAX 800 is a newer platform. This study is being done to see if the newer VISUMAX 800 provides the same or better results than the VISUMAX 500.",[84],"Myopia",[86,87,88,89],"SMILE","Visumax","Refractive surgery","RCT","2026-03-26",{"date":92,"type":36},"2026-04-01",{"date":94,"type":36},"2025-12-01",{"date":96,"type":20},"2027-06",{"name":42,"class":43},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":108,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":72},"100611675","glaucoma-screening-using-artificial-intelligence-assisted-clinical-model-in-singapores-diabetic-eye-screening-program-100611675","NCT07243665","Glaucoma Screening Using Artificial Intelligence Assisted Clinical Model in Singapore's Diabetic Eye Screening Program","A Pragmatic Randomized Controlled Trial of a New Artificial Intelligence-Assisted Clinical Model in Opportunistic Screening for Glaucoma in the Singapore Integrated Diabetic Retinopathy Program","AIGS","Inclusion Criteria: We aim to recruit all eligible patients who attend Singapore General Hospital (SGH) Diabetes \\& Metabolism Centre's (DMC) clinics and SingHealth Polyclinics (SHP)-Bukit Merah under the Singapore Integrated Diabetic Retinopathy Programme (SiDRP). Patients are eligible for the study if\n\n1. Aged 21 years old and above, with diabetes, including type 1 and type 2,\n2. Retinal photos of the patients can be taken with the fundus camera in the clinics, regardless of photos' quality, and\n3. They are willing and capable of providing a written informed consent form.\n\nExclusion Criteria: Patients meeting any of the exclusion criteria will be excluded from participation:\n\n1. Patients who have difficulty in having retinal photos taken or have difficulties in completing the ocular examination protocols according to investigator's decision.\n2. Any other contraindication(s) as indicated by the endocrinologists responsible for the patients.\n\n   \\-",{"count":107,"type":20},1040,[23],"Glaucoma is major cause of irreversible blindness and is characterized by optic nerve damage and visual field loss. Screening for glaucoma is challenging due to lack of a simple, accurate, cost-efficient and standardized process. Artificial intelligence, (AI) especially deep learning (DL) algorithms have potential to automate glaucoma detection, but have to be evaluated in real world settings, before public deployment. This study aims to evaluate the screening accuracy of a DL algorithm for glaucoma detection using colour fundus photographs (CFP) in a pragmatic randomised control trial (RCT). The algorithm will be tested in 1040 eligible patients with diabetes, recruited from the Diabetes \\& Metabolism Centre's clinics under the Singapore Integrated Diabetic Retinopathy Program (SiDRP) and randomized to 2 arms: AI-assisted model vs current standard of care (grader assessment). The performance of both arms will be compared to performance of study ophthalmologist in diagnosing glaucoma. We hypothesize that the DL model has better screening performance in detecting glaucoma in the community, compared to the current practice method.",[111],"Glaucoma",[111,113,114,115,116,117],"deep learning","fundus photos","artificial intelligence","randomised controlled trial","screening","2026-01-27",{"date":120,"type":36},"2026-01-29",{"date":122,"type":36},"2025-11-17",{"date":124,"type":20},"2027-03",{"name":42,"class":43},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":21,"phases":134,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":72},"100606375","efficacy-of-quantum-molecular-resonance-in-neuropathic-corneal-pain-and-corneal-nerve-regeneration-100606375","NCT07174739","Efficacy of Quantum Molecular Resonance in Neuropathic Corneal Pain and Corneal Nerve Regeneration","Inclusion Criteria:\n\n* Be at least 21 years of age.\n* Regardless of gender (Male\u002FFemale).\n* Regardless of race (Chinese\u002FMalay\u002FIndian\u002FEurasian\u002FOthers).\n* Diagnosed with neuropathic corneal pain based on the following criteria: presence of neuropathic ocular symptoms (burning, stinging, photophobia, pain, severe dryness), absent or minimal slit-lamp findings to explain the symptoms and corneal nerve abnormalities as detected by IVCM (decreased corneal length and density, presence of neuromas).\n* Willing to receive all eye examinations in this study.\n\nExclusion Criteria:\n\n* Pregnant women.\n* Participants carrying active implantable devices (e.g., pacemakers and hearing aids).\n* Oncologic patients under treatment; patient who underwent ocular surgery in the last month.\n* Participants who had ocular infection within 6 months, or active ocular infection or inflammation; any concomitant ocular diseases that could potentially induce ocular pain, such as uveitis.",{"count":133,"type":20},30,[23],"The goal of this study is to evaluate whether Quantum Molecular Resonance (QMR) treatment can effectively reduce eye pain and stimulate corneal nerve regeneration in patients with neuropathic corneal pain (NCP). Participants diagnosed with NCP will attend a total of nine study visits, consisting of one baseline assessment and eight QMR treatment sessions. At each visit, participants will undergo a series of clinical examinations to evaluate changes in the ocular surface, corneal nerves, and tear proteins, and will complete questionnaires regarding their symptoms, eye pain, and quality of life. The investigators will compare these outcomes before and after QMR treatment to determine whether QMR treatment alleviates NCP symptoms and enhances ocular surface and corneal nerve health. The investigators hypothesize that QMR treatment will provide notable pain relief, promote corneal nerve regeneration, and improve overall quality of life for NCP patients.",[137],"Neuropathic Corneal Pain",[139,140,141,142,143],"neuropathic corneal pain","eye pain","QMR","Quantum Molecular Resonance","Rexon-Eye","2025-09-15",{"date":146,"type":36},"2025-09-19",{"date":148,"type":36},"2023-11-01",{"date":150,"type":20},"2026-12-31",{"name":42,"class":43},{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":21,"phases":162,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":72},"100387062","phase-1-safety-and-efficacy-of-tissue-engineered-endothelial-keratoplasty-100387062","NCT04319848","Safety and Efficacy of Tissue Engineered Endothelial Keratoplasty","Safety and Efficacy of Tissue Engineered Endothelial Keratoplasty (TE-EK)","TE-EK","Inclusion Criteria:\n\nPatients who have mild to moderate corneal endothelial decompensation or bullous keratopathy, but with minimal corneal stromal scarring resulting from a variety of conditions including:\n\n* Fuchs' endothelial dystrophy\n* Post-surgical corneal decompensation (irreversible) - all forms of pseudophakic or aphakic bullous keratopathy\n\nExclusion Criteria:\n\n* Severe forms or late stage presentation of corneal decompensation with severe corneal stromal scarring, unsuitable for TE-EK surgery as opposed to penetrating keratoplasty\n* Patients with complex anterior segment complications precluding a successful TE-EK procedure\n* Patients who have other forms of endothelial dystrophy, traumatic corneal decompensation, or post-inflammatory corneal decompensation\n* Post-laser iridotomy or glaucoma related corneal decompensation\n* Patients not keen to participate in the clinical trial\n* Patients who are below 21 years of age or above 80 years of age\n* Patients who are pregnant\n* Patients who are cognitively impaired\n* Patients who are prisoners\n* Patients who are allergic to antibiotics","80 Years",{"count":133,"type":20},[163],"PHASE1","Assessment of safety and efficacy of tissue-engineered corneal endothelial graft material generated using cultured human corneal endothelial cells for tissue-engineered endothelial keratoplasty (TE-EK).",[166,167,168,169],"Mild to Moderate Corneal Endothelial Decompensation","Bullous Keratopathy","Fuchs' Endothelial Dystrophy","Post-surgical Corneal Decompensation (Irreversible)","2025-09-05",{"date":172,"type":36},"2025-09-12",{"date":174,"type":36},"2017-12-01",{"date":176,"type":20},"2028-06",{"name":42,"class":43},{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":187,"phases":4,"briefSummary":188,"conditions":189,"keywords":193,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":72},"100591686","validation-of-the-use-of-terahertz-scanning-system-on-corneal-scars-and-corneal-edema-100591686","NCT06983652","Validation of the Use of Terahertz Scanning System on Corneal Scars and Corneal Edema","Validation of the Use of Terahertz Scanning System on Corneal Scars and Corneal Edema: Phase II Clinical Trial","Inclusion Criteria:\n\n* Be at least 21 years of age.\n* Regardless of gender (Male\u002FFemale).\n* Regardless of race (Chinese\u002FMalay\u002FIndian\u002FEurasian\u002FOthers).\n* Willingness and ability to follow all instructions and comply with study schedule for study visit.\n* Patients with corneal endothelial dysfunction (Fuchs' endothelial dystrophy or other causes of bullous keratopathy) at any disease stage OR Patients with corneal scars from any cause, with the absence of corneal edema.\n* Ability to hold face sufficiently stable to undergo necessary scans.\n\nExclusion Criteria:\n\n* Eyes with active inflammation or infection, or chronic ocular surface inflammation\n* Unable to give consent\n* Physically immobile\u002Fpoor instructional compliance\n* PI determined\n* Pregnant\u002F breast feeding women",{"count":186,"type":20},150,"OBSERVATIONAL","This observational study aims to validate the use of THz scanning system in corneal edema and corneal scars, and to investigate the accuracy and performance on the use of THz scanning system in the evaluation of the progression of corneal edema and corneal scars. Participants corneal scars and corneal edema will undergo THz scanning, followed by a series of conventional clinical examinations for detailed characterization of the corneal lesion. The performance of the use of THz system on corneal scars and edema will be evaluated by correlating measurements from the THz scans with those obtained from standard clinical methods. The investigators hypothesize that the THz scanning system has the capacity to evaluate the hydration level on human corneas.",[190,191,192],"Corneal Diseases","Corneal Scars and Opacities","Corneal Edema",[194,195,196,197,198],"cornea","corneal scar","corneal edema","Terahertz","hydration","2025-05-14",{"date":201,"type":36},"2025-05-21",{"date":203,"type":36},"2024-07-01",{"date":205,"type":20},"2026-08-31",{"name":42,"class":43},{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":187,"phases":4,"briefSummary":216,"conditions":217,"keywords":218,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":72},"100590467","evaluation-of-the-safety-of-terahertz-scanning-system-on-corneas-100590467","NCT06967792","Evaluation of the Safety of Terahertz Scanning System on Corneas","Evaluation of the Safety of Terahertz Scanning System on Corneas: Phase I Trial","Inclusion Criteria:\n\n* Be at least 21 years of age\n* Regardless of gender (Male\u002FFemale)\n* Regardless of race (Chinese\u002FMalay\u002FIndian\u002FEurasian\u002FOthers)\n* Willingness and ability to follow all instructions and comply with study schedule for study visit\n* Have at least 1 eye (Study eye) that is deemed functionally blind but contain healthy corneas\n* Ability to hold face sufficiently stable to undergo necessary scans\n* Best Spectacle Corrected Visual Acuity (BSCVA) in the study eye of hand motion or worse\n\nExclusion Criteria:\n\n* Pregnant\u002FBreast-feeding women\n* Eyes with previous major surgery on the cornea such as corneal transplantation, refractive surgery, corneal cross-linking procedure\n* Eyes with previous infectious keratitis\n* Eyes with long-term use of glaucoma eye drops\n* Eyes with known moderate or server meibomian gland dysfunction\n* Eyes with active inflammation or infection, or chronic ocular surface inflammation\n* Systemic diseases that affect the ocular surface, such as systemic autoimmune diseases",{"count":215,"type":20},5,"This observational study aims to establish the safety profile of the use of Terahertz (THz) scanning system on corneal diseases. Participants with \"non-seeing\" eyes but normal corneas will undergo THz scanning. Eye examinations will be conducted at baseline, immediately after scanning, and at 1 day, 1 week, and 1 month post-scanning. These examinations will include measurements of visual acuity, eye structural, retinal health, corneal cell morphology, and corneal nerve status. The investigators hypothesize that the THz scanning system is safe for application to the human cornea.",[190],[194,196,197,198],"2025-05-13",{"date":221,"type":36},"2025-05-16",{"date":223,"type":36},"2024-04-01",{"date":225,"type":20},"2026-04-30",{"name":42,"class":43},{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":17,"minAge":234,"maxAge":235,"enrollmentInfo":236,"targetDuration":4,"studyType":21,"phases":238,"briefSummary":240,"conditions":241,"keywords":243,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":72},"100519809","phase-3-the-effects-of-ripasudil-in-patients-with-fed-undergoing-femtosecond-laser-assisted-cataract-surgery-100519809","NCT06048380","The Effects of Ripasudil in Patients With FED Undergoing Femtosecond Laser Assisted Cataract Surgery","The Effects of Ripasudil in Patients With Fuchs Endothelial Corneal Dystrophy Undergoing Femtosecond Laser Assisted Cataract Surgery","Inclusion Criteria:\n\n1. Patients with FED who will be listed for cataract surgery as part of standard clinical practice (A cataract will be defined as clouding of the lens that interferes with normal vision).\n2. Only patients older than 50 years will be included, as cataracts develops with increasing age. No gender criteria are applied.\n3. Ability to provide informed consent, and are willing and able to sign a written Informed Consent Form prior to any study-specific procedures.\n4. Patients must be willing and able to return for scheduled follow-up examinations for up to 12 months after the surgery.\n\nExclusion Criteria:\n\n1. Patients who are unable to give consent.\n2. An only-functioning eye in a patient who has lost visual potential in the contralateral eye.\n3. Diagnosis of clinically relevant eye diseases that may interfere with the aim of the study.\n4. History of ripasudil use, as well as other systemic disease such as cardiovascular or renal disease.\n5. Patients who have previous allergic reactions to the contents present in Glanatec Ophthalmic solution 0.4%","50 Years","100 Years",{"count":237,"type":20},120,[239],"PHASE3","The purpose of this research is to investigate the effects of ripasudil administered as an ophthalmic solution in patients with FED after femtosecond laser assisted cataract surgery. The secondary aim is to identity the characteristics of patients who will benefit the most with the use of ripasudil based on the test results obtained from this study.",[168,242],"Cataract",[244],"Ripasudil","2025-01-27",{"date":247,"type":36},"2025-01-29",{"date":249,"type":20},"2025-03-01",{"date":251,"type":20},"2025-07",{"name":42,"class":43},{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":259,"sex":17,"minAge":50,"maxAge":234,"enrollmentInfo":260,"targetDuration":4,"studyType":187,"phases":4,"briefSummary":262,"conditions":263,"keywords":264,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":72},"100575620","comparison-of-femto-ldv-z8-corneal-lenticule-extraction-for-advanced-refractive-correction-clear-and-visumax-small-incision-lenticule-extraction-smile-100575620","NCT06774651","Comparison of Femto LDV Z8 Corneal Lenticule Extraction for Advanced Refractive Correction (CLEAR) and Visumax Small Incision Lenticule Extraction (SMILE)","Inclusion Criteria:\n\n* \\>\u002F= 21 years of age and \\\u003C\u002F= 50 years of age.\n* Cycloplegic spherical equivalent of \\>-1.00D\n* Refractive cylinder -2.00 D or less; anisometropia \\\u003C1.00D\n* Best spectacle corrected visual acuity (BSCVA) of 6\u002F12 or better in BOTH eyes.\n* Spherical or cylindrical error has progressed at -0.50D or less per year from date of baseline measurement.\n* Contact lens wearers must have removed contact lenses at least two (2) weeks before the baseline measurement.\n* No evidence of irregular astigmatism on corneal topography.\n* Available to attend post-operative examinations for a 12-month period.\n\nExclusion Criteria:\n\n* Progressive or unstable myopia and\u002For astigmatism.\n* Clinical or corneal topographic evidence of keratoconus.\n* Patients who want bilateral SMILE procedure\n* Patients who want extracted corneal lenticule to be stored for future refractive surgery.\n* Residual, recurrent or active ocular disease such as uveitis, severe dry eyes, severe allergic eye disease, glaucoma, visually significant cataract and retinal disease.\n* Previous corneal surgery or trauma within the corneal treatment zone.\n* Corneal vascularisation within 1mm of the corneal treatment zone.\n* Taking systemic medications likely to affect wound healing, such as corticosteroids and antimetabolites.\n* Systemically immunocompromised.\n* Systemic disease likely to affect wound healing, such as diabetes, connective tissue disease and severe atopy.\n* Pregnant or nursing.",true,{"count":261,"type":20},65,"This observational study aims to compare two laser corrective procedures for treating myopia and myopic astigmatism: a novel refractive technique, the CLEAR procedure, and the established SMILE procedure. Participants will be randomized to undergo CLEAR in one eye and SMILE in the other. The investigators will evaluate and compare the two procedures based on the following aspects: refractive predictability (how accurate the vision correction is) by measuring the proportion of eyes close to the target prescription after surgery, clinical dry eye outcomes, changes in tear proteins, and corneal nerve changes at 1, 3, 6, and 12 months after both surgeries. Metabolomic features of the removed corneal tissue and how precisely the laser is centered during surgery will also be examined. Our hypothesis is that CLEAR provides equally good vision results as SMILE, and explore any extra benefits of CLEAR.",[84],[265,266,86,87,84],"CLEAR","FEMTO LDV Z8","2025-01-08",{"date":269,"type":36},"2025-01-14",{"date":271,"type":36},"2023-03-01",{"date":273,"type":20},"2025-12-31",{"name":42,"class":43},""]